logo
logo

Octave Bioscience announced it raised $31.8 Million in an initial filing from an offering of $53.7 Million

Mar 24, 20254 months ago

Amount Raised

$31.8 Million

Menlo ParkBiotechnology

Company Information

Company

Octave

Location

Menlo Park, California, United States

About

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People